Wyślij emailem: A Phase I Study of EZN-3042, a Novel Survivin Messenger Ribonucleic Acid (mRNA) Antagonist, Administered in Combination with Chemotherapy in Children with Relapsed Acute Lymphoblastic Leukemia (ALL): A Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium